Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Journal of Translational Internal Medicine

4 Issues per year

Open Access
See all formats and pricing
More options …

Systemic corticosteroids in acute exacerbation of chronic obstructive pulmonary disease

Vincent Ninane
Published Online: 2015-04-24 | DOI: https://doi.org/10.4103/2224-4018.135609


Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) lead to a significant decrease in pulmonary function and quality of life and an increase in mortality. However, systemic use of corticosteroids is able to improve the conditions of patients in AECOPD. By a short review of several clinical trials, we suggest that 40 mg prednisone per day for 5 days should be recommended for the treatment of AECOPD with a preference for oral prednisolone.

Keywords: corticosteroids; systemic use; prednisolone; acute exacerbations; chronic obstructive pulmonary disease


  • 1. Leuppi JD, Schuetz P, Bingisser R, Bodmer M, Briel M, Drescher T, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA 2013;309:2223-31.Web of ScienceGoogle Scholar

  • 2. Abroug F, Ouanes-Besbes L, Fkih-Hassen M, Ouanes I, Ayed S, Dachraoui F, et al. Prednisone in COPD exacerbation requiring ventilatory support: an open-label randomised evaluation. Eur Respir J 2014;43:717-24.Web of ScienceGoogle Scholar

  • 3. Kiser TH, Allen RR, Valuck RJ, Moss M, Vandivier RW. Outcomes associated with corticosteroid dosage in critically ill patients with acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2014;189:1052-64.Google Scholar

About the article

Published Online: 2015-04-24

Published in Print: 2014-06-01

Citation Information: Journal of Translational Internal Medicine, Volume 2, Issue 2, Pages 81–82, ISSN (Online) 2224-4018, DOI: https://doi.org/10.4103/2224-4018.135609.

Export Citation

© 2015. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License. BY-NC-ND 3.0

Comments (0)

Please log in or register to comment.
Log in